Towards Healthcare
Autologous Stem Cell & Non-stem Cell Therapies Market to Grow 32.26% CAGR by 2...

Autologous Stem Cell & Non-stem Cell Therapies Market Growth 2025 to 2034 AI Integration, CAR-T Advancements & Global Expansion

Based on market forecasts, the autologous stem cell & non-stem cell therapies sector will expand from USD 5.15 billion in 2024 to USD 82.32 billion by 2034, experiencing a CAGR of 32.26%. The autologous stem cell & non-stem cell therapies market is growing due to rising demand in cancer care. North America is dominating due to the growing number of cell therapy clinical trials.

  • Insight Code: 6017
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The autologous stem cell & non-stem cell therapies market in 2025 is valued at USD 6.81 billion and is projected to climb to USD 82.32 billion by 2034, with a CAGR of 32.26% over the forecast period.

North America is currently leading the autologous stem cell & non-stem cell therapies market due to rising demand for precision medicine.

Some key players include Gilead Sciences Kite Pharma, Novartis, Bristol-Myers Squibb, Vericel Corporation, Dendreon (PROVENGE), Mesoblast, etc. 

Key trends include rising demand for personalized medicine and growing demand for therapeutics for rare diseases.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.